Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer
暂无分享,去创建一个
M. Dowsett | S. Château-Joubert | L. Zabaglo | S. Johnston | E. Schuster | S. Pancholi | Lesley-Ann Martin | M. Leal | Q. Gao | S. Cosulich | A. Dodson | Ricardo Ribas | M. Hills | Nikiana Simigdala | Elisabetta Maragoni | S. Chateau-Joubert | L. Martin